×
About 2,493 results

ALLMedicine™ Neuromuscular Diseases Center

Research & Reviews  1,221 results

Screening for oropharyngeal dysphagia in adult patients with neuromuscular diseases usi...
https://doi.org/10.1002/mus.27254
Muscle & Nerve; Audag N, Liistro G et. al.

Apr 23rd, 2021 - Oropharyngeal dysphagia is common in patients with neuromuscular diseases (NMDs). Its early recognition is vital for proper management. We tested a large cohort of adult NMD patients for oropharyngeal dysphagia using the Sydney Swallow Questionnai...

Validation of forward simulations to predict the effects of bilateral plantarflexor wea...
https://doi.org/10.1016/j.gaitpost.2021.04.020
Gait & Posture; Waterval NFJ, Veerkamp K et. al.

Apr 21st, 2021 - Bilateral plantarflexor muscle weakness is a common impairment in many neuromuscular diseases. However, the way in which severity of plantarflexor weakness affects gait in terms of walking energy cost and speed is not fully understood. Predictive ...

Electrodiagnostic Testing for Disorders of Peripheral Nerves.
https://doi.org/10.1016/j.cger.2021.01.010
Clinics in Geriatric Medicine; Choi JM, Di Maria G

Apr 16th, 2021 - Nerve conduction studies and electromyography are useful diagnostic tools that neurologists use to diagnose diseases of the peripheral nerves, neuromuscular junction, and muscles. These tests are considered an extension of clinical history and exa...

Understanding the relationship between the 32-item motor function measure and daily act...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011105
BMC Neurology; Duong T, Braid J et. al.

Apr 1st, 2021 - The 32-item Motor Function Measure (MFM32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular diseases, including those with spinal muscular atrophy (SMA). This two-part study explored...

State-of-the art review: Noncompaction cardiomyopathy in pediatric patients.
https://doi.org/10.1007/s10741-021-10089-7 10.1161/CIRCULATIONAHA.106.174287 10.1016/0002-9149(84)90618-0 10.1136/heart.86.6.666 10.1161/CIRCRESAHA.116.309386 10.1161/CIRCULATIONAHA.117.032262 10.1177/1753944713504639 10.1253/circj.CJ-16-1114 10.1017/S1047951105000752 10.1007/BF02577920 10.1016/j.jacc.2017.12.019 10.1002/uog.12279 10.1007/s00246-016-1369-8 10.1097/00000441-193204000-00003 10.1093/eurheartj/ehm342 10.1007/978-3-030-17720-1_2 10.1016/j.cardfail.2015.06.381 10.1007/s12024-017-9889-y 10.1007/s12024-014-9637-5 10.1055/s-0029-1240551 10.1016/S0828-282X(09)70151-5 10.1111/j.1540-8175.2008.00740.x 10.1161/CIRCULATIONAHA.113.002511 10.1016/j.amjcard.2004.08.047 10.1067/mje.2002.128212 10.1510/icvts.2010.246694 10.1016/j.hlc.2017.01.013 10.1007/s00246-010-9868-5 10.1111/j.1747-0803.2009.00269.x 10.1007/s00246-008-9382-1 10.2459/JCM.0b013e32801462b0 10.1093/eurheartj/ehl112 10.1007/s00059-018-4695-1 10.2174/138161210793176437 10.1136/hrt.76.4.380 10.1186/1532-429X-15-67 10.1016/j.ijcard.2012.12.058 10.1016/j.echo.2011.09.019 10.1111/j.1442-200X.2007.02339.x 10.1002/pd.4523 10.1016/j.jchf.2014.02.010 10.1007/s00246-015-1200-y 10.1016/j.siny.2017.11.006 10.1016/j.jacc.2016.05.096 10.1007/s00246-008-9359-0 10.1038/nrcardio.2016.207 10.1016/j.jacc.2018.12.085 10.1161/CIRCULATIONAHA.107.746164 10.1161/CIRCGENETICS.109.861955 10.1038/415227a 10.1161/CIRCRESAHA.117.310987 10.1086/514879 10.1186/1750-1172-8-23 10.1002/ajmg.a.35609 10.1002/ajmg.a.20075 10.1016/j.mito.2010.02.003 10.1161/01.CIR.0000100664.10777.B8 10.1016/j.healun.2015.12.010 10.1016/S0002-9149(02)02723-6 10.1016/S0735-1097(00)00755-5 10.1093/eurheartj/ehm481 10.1016/j.jacc.2005.03.045 10.1093/eurheartj/ehp595 10.1016/j.jacc.2016.08.054 10.1016/S0735-1097(99)00170-9 10.1007/s00246-015-1330-2 10.1016/j.ijcard.2015.04.046 10.1111/jocs.13088 10.1093/ejcts/ezx385 10.1097/MBC.0b013e32835bfd85
Heart Failure Reviews; Rohde S, Muslem R et. al.

Mar 14th, 2021 - Noncompaction cardiomyopathy (NCCM) is a disease characterized by hypertrabeculation, commonly hypothesized due to an arrest in compaction during fetal development. In 2006, NCCM was classified as a distinct form of cardiomyopathy (CMP) by the Ame...

see more →

Guidelines  5 results

Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific ...
https://doi.org/10.1161/CIR.0000000000000526
Circulation Feingold B, Mahle WT et. al.

Aug 25th, 2017 - For many neuromuscular diseases (NMDs), cardiac disease represents a major cause of morbidity and mortality. The management of cardiac disease in NMDs is made challenging by the broad clinical heterogeneity that exists among many NMDs and by limit...

MDA U.S. Neuromuscular Disease Registry
https://www.mda.org/services/neuromuscular-disease-registry
Muscular Dystrophy Association (USA)

Dec 31st, 2015 - In 2013, MDA launched the U. S.

An official American Thoracic Society statement: update on the mechanisms, assessment, ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448624
American Journal of Respiratory and Critical Care Medicine; Parshall MB, Schwartzstein RM et. al.

Feb 17th, 2012 - Dyspnea is a common, distressing symptom of cardiopulmonary and neuromuscular diseases. Since the ATS published a consensus statement on dyspnea in 1999, there has been enormous growth in knowledge about the neurophysiology of dyspnea and increasi...

CONSENSUS STATEMENT: THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF NEUROMUSCULAR...
http://www.aanem.org/getmedia/e39a0191-ee38-48fe-9b43-e580228825a7/IVIG_CS_2009.pdf
PETER D. DONOFRIO

Sep 17th, 2009 - Consensus statements are important for developing treatment recommendations when evidence- based medicine (EBM) and treatment based on controlled trials is sparse or nonexistent. In this setting, it is clinically helpful to assemble a group of exp.

COVID-19: Guidelines for Myasthenia Gravis Management and Other Neuromuscular Disorders
https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=950

​If your patients have myasthenia gravis, should they come in for an infusion therapy? Is it safe to start patients on a new B-cell depleting therapy? And should patients stop their immunosuppressive therapies? As the COVID-19 pandemic rages on, n...

see more →

Clinicaltrials.gov  1,245 results

Screening for oropharyngeal dysphagia in adult patients with neuromuscular diseases usi...
https://doi.org/10.1002/mus.27254
Muscle & Nerve; Audag N, Liistro G et. al.

Apr 23rd, 2021 - Oropharyngeal dysphagia is common in patients with neuromuscular diseases (NMDs). Its early recognition is vital for proper management. We tested a large cohort of adult NMD patients for oropharyngeal dysphagia using the Sydney Swallow Questionnai...

Validation of forward simulations to predict the effects of bilateral plantarflexor wea...
https://doi.org/10.1016/j.gaitpost.2021.04.020
Gait & Posture; Waterval NFJ, Veerkamp K et. al.

Apr 21st, 2021 - Bilateral plantarflexor muscle weakness is a common impairment in many neuromuscular diseases. However, the way in which severity of plantarflexor weakness affects gait in terms of walking energy cost and speed is not fully understood. Predictive ...

Electrodiagnostic Testing for Disorders of Peripheral Nerves.
https://doi.org/10.1016/j.cger.2021.01.010
Clinics in Geriatric Medicine; Choi JM, Di Maria G

Apr 16th, 2021 - Nerve conduction studies and electromyography are useful diagnostic tools that neurologists use to diagnose diseases of the peripheral nerves, neuromuscular junction, and muscles. These tests are considered an extension of clinical history and exa...

Understanding the relationship between the 32-item motor function measure and daily act...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011105
BMC Neurology; Duong T, Braid J et. al.

Apr 1st, 2021 - The 32-item Motor Function Measure (MFM32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular diseases, including those with spinal muscular atrophy (SMA). This two-part study explored...

State-of-the art review: Noncompaction cardiomyopathy in pediatric patients.
https://doi.org/10.1007/s10741-021-10089-7 10.1161/CIRCULATIONAHA.106.174287 10.1016/0002-9149(84)90618-0 10.1136/heart.86.6.666 10.1161/CIRCRESAHA.116.309386 10.1161/CIRCULATIONAHA.117.032262 10.1177/1753944713504639 10.1253/circj.CJ-16-1114 10.1017/S1047951105000752 10.1007/BF02577920 10.1016/j.jacc.2017.12.019 10.1002/uog.12279 10.1007/s00246-016-1369-8 10.1097/00000441-193204000-00003 10.1093/eurheartj/ehm342 10.1007/978-3-030-17720-1_2 10.1016/j.cardfail.2015.06.381 10.1007/s12024-017-9889-y 10.1007/s12024-014-9637-5 10.1055/s-0029-1240551 10.1016/S0828-282X(09)70151-5 10.1111/j.1540-8175.2008.00740.x 10.1161/CIRCULATIONAHA.113.002511 10.1016/j.amjcard.2004.08.047 10.1067/mje.2002.128212 10.1510/icvts.2010.246694 10.1016/j.hlc.2017.01.013 10.1007/s00246-010-9868-5 10.1111/j.1747-0803.2009.00269.x 10.1007/s00246-008-9382-1 10.2459/JCM.0b013e32801462b0 10.1093/eurheartj/ehl112 10.1007/s00059-018-4695-1 10.2174/138161210793176437 10.1136/hrt.76.4.380 10.1186/1532-429X-15-67 10.1016/j.ijcard.2012.12.058 10.1016/j.echo.2011.09.019 10.1111/j.1442-200X.2007.02339.x 10.1002/pd.4523 10.1016/j.jchf.2014.02.010 10.1007/s00246-015-1200-y 10.1016/j.siny.2017.11.006 10.1016/j.jacc.2016.05.096 10.1007/s00246-008-9359-0 10.1038/nrcardio.2016.207 10.1016/j.jacc.2018.12.085 10.1161/CIRCULATIONAHA.107.746164 10.1161/CIRCGENETICS.109.861955 10.1038/415227a 10.1161/CIRCRESAHA.117.310987 10.1086/514879 10.1186/1750-1172-8-23 10.1002/ajmg.a.35609 10.1002/ajmg.a.20075 10.1016/j.mito.2010.02.003 10.1161/01.CIR.0000100664.10777.B8 10.1016/j.healun.2015.12.010 10.1016/S0002-9149(02)02723-6 10.1016/S0735-1097(00)00755-5 10.1093/eurheartj/ehm481 10.1016/j.jacc.2005.03.045 10.1093/eurheartj/ehp595 10.1016/j.jacc.2016.08.054 10.1016/S0735-1097(99)00170-9 10.1007/s00246-015-1330-2 10.1016/j.ijcard.2015.04.046 10.1111/jocs.13088 10.1093/ejcts/ezx385 10.1097/MBC.0b013e32835bfd85
Heart Failure Reviews; Rohde S, Muslem R et. al.

Mar 14th, 2021 - Noncompaction cardiomyopathy (NCCM) is a disease characterized by hypertrabeculation, commonly hypothesized due to an arrest in compaction during fetal development. In 2006, NCCM was classified as a distinct form of cardiomyopathy (CMP) by the Ame...

see more →

News  19 results

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals
https://www.reuters.com/article/us-exonics-therapeutics-m-a-vertex-pharm/vertex-pharmaceuticals-expands-into-duchenne-gene-therapy-with-new-deals-idUSKCN1T72YK

Jun 6th, 2019 - (Reuters) - Vertex Pharmaceuticals Inc said here on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million. Exonics Therapeutics develops gene edi...

Conditional EU Approval of Muscular Dystrophy Drug Applauded
https://www.medscape.com/viewarticle/829486

Aug 5th, 2014 - The Muscular Dystrophy Association (MDA), a nonprofit health agency dedicated to finding treatments and cures for neuromuscular diseases, has applauded the decision by the European Union (EU) to conditionally approve ataluren (Translarna, PTC Ther...

Focusing on pediatrics: New initiatives from CHEST
https://www.mdedge.com/chestphysician/article/84476/pediatrics/focusing-pediatrics-new-initiatives-chest
Dr. Mary Cataletto, FCCP, FAAP

Jul 14th, 2014 - This year, the American College of Chest Physicians (CHEST) is proud to announce some new initiatives focusing on important issues in respiratory health and disease in infants, children, and adolescents. As treatment advances allow longer and bett.

Tirasemtiv: Initial Promise in Myasthenia Gravis
https://www.staging.medscape.com/viewarticle/781881

Apr 2nd, 2013 - San Diego, California — The investigational drug tirasemtiv (Cytokinetics), which is being studied for the first indication of amyotrophic lateral sclerosis (ALS), may also have a role in myasthenia gravis, preliminary data suggest. Presenting the...

Tirasemtiv: Initial Promise in Myasthenia Gravis
https://www.medscape.com/viewarticle/781881

Apr 2nd, 2013 - San Diego, California — The investigational drug tirasemtiv (Cytokinetics), which is being studied for the first indication of amyotrophic lateral sclerosis (ALS), may also have a role in myasthenia gravis, preliminary data suggest. Presenting the...

see more →

Patient Education  3 results see all →